“…12,36,37 A deregulation in the antiapoptotic CDK9-signaling system may lead to malignant cell transformation, as reported in a number of other systems, such as insulin-like growth factor-I receptor, epidermal growth factor receptor, autocrine/ paracrine secreted Frizzled-related protein 2, AKTrelated pathway and surviving. [38][39][40][41] A deregulated CDK9-related pathway was observed in several human tumors: lymphomas, 14,30,42 neuroblastoma, 17 primary neuroectodermal tumor (PNET), 17 rhabdomyosarcoma 31 and prostate cancer. 32 For instance, an imbalance in CDK9 and Cyclin T1 mRNA was observed in several hematopoietic malignancies: follicular lymphoma, diffuse large B-cell lymphoma with germinal center phenotype, Burkitt's lymphoma and cell lines of classical Hodgkin's lymphoma.…”